Long COVID in a prospective cohort of home-isolated patients

Bjørn Blomberg, Kristin Greve-Isdahl Mohn, Karl Albert Brokstad, Fan Zhou, Dagrun Waag Linchausen, Bent-Are Hansen, Sarah Lartey, Therese Bredholt Onyango, Kanika Kuwelker, Marianne Sævik, Hauke Bartsch, Camilla Tøndel, Bård Reiakvam Kittang, Bergen COVID-19 Research Group, Rebecca Jane Cox, Nina Langeland, Anders Madsen, Geir Bredholt, Juha Vahokoski, Elisabeth Berg Fjelltveit, Amit Bansal, Mai Chi Trieu, Sonja Ljostveit, Jan Stefan Olofsson, Nina Ertesvåg, Helene Heitmann Sandnes, Anette Corydon, Hanne Søyland, Marianne Eidsheim, Kjerstin Jakobsen, Nina Guldseth, Synnøve Hauge, Bjørn Blomberg, Kristin Greve-Isdahl Mohn, Karl Albert Brokstad, Fan Zhou, Dagrun Waag Linchausen, Bent-Are Hansen, Sarah Lartey, Therese Bredholt Onyango, Kanika Kuwelker, Marianne Sævik, Hauke Bartsch, Camilla Tøndel, Bård Reiakvam Kittang, Bergen COVID-19 Research Group, Rebecca Jane Cox, Nina Langeland, Anders Madsen, Geir Bredholt, Juha Vahokoski, Elisabeth Berg Fjelltveit, Amit Bansal, Mai Chi Trieu, Sonja Ljostveit, Jan Stefan Olofsson, Nina Ertesvåg, Helene Heitmann Sandnes, Anette Corydon, Hanne Søyland, Marianne Eidsheim, Kjerstin Jakobsen, Nina Guldseth, Synnøve Hauge

Abstract

Long-term complications after coronavirus disease 2019 (COVID-19) are common in hospitalized patients, but the spectrum of symptoms in milder cases needs further investigation. We conducted a long-term follow-up in a prospective cohort study of 312 patients-247 home-isolated and 65 hospitalized-comprising 82% of total cases in Bergen during the first pandemic wave in Norway. At 6 months, 61% (189/312) of all patients had persistent symptoms, which were independently associated with severity of initial illness, increased convalescent antibody titers and pre-existing chronic lung disease. We found that 52% (32/61) of home-isolated young adults, aged 16-30 years, had symptoms at 6 months, including loss of taste and/or smell (28%, 17/61), fatigue (21%, 13/61), dyspnea (13%, 8/61), impaired concentration (13%, 8/61) and memory problems (11%, 7/61). Our findings that young, home-isolated adults with mild COVID-19 are at risk of long-lasting dyspnea and cognitive symptoms highlight the importance of infection control measures, such as vaccination.

Conflict of interest statement

The authors declare no competing interests.

© 2021. The Author(s).

Figures

Fig. 1. Study population flow chart.
Fig. 1. Study population flow chart.
Number of participants eligible for inclusion at baseline, blood sampling at 2 months and assessment and fatigue evaluation at 6 months. BMEC, Bergen Municipality Emergency Clinic; LTF, lost to follow-up.
Fig. 2. Six-month follow-up of patients with…
Fig. 2. Six-month follow-up of patients with COVID-19 in Bergen, Norway.
The relationship of severity of initial COVID-19 illness and of age with anti-SARS-CoV-2 spike (a and b) and microneutralizing antibody titers (e and f) at 2 months. The relationship of antibody titers at 2 months with number of persistent symptoms (c and g) and total fatigue score according to the Chalder scale (d and h) at 6-month follow-up. The 13 symptoms used are listed in Table 2. The severity of illness was as follows: 1—asymptomatic (n = 5); 2—home-isolated with symptoms (n = 242); 3—hospitalized without medical needs (n = 0); 4—hospitalized with medical needs (n = 31); 5—hospitalized needing O2 (n = 24); 6—hospitalized needing non-invasive ventilation (n = 4); and 7—hospitalized needing respirator (n = 6). The cohort was divided into 15-year age groups: 0–15 (n = 16), 16–30 (n = 65), 31–45 (n = 69), 46–60 (n = 90) and >60 (n = 72). a, b, e and f show median spike IgG and microneutralizing antibody titers (horizontal line), 25% and 75% quantiles (box), plus 95% confidence intervals (lines) with outliers (dots). c and d are violin plots of number of symptoms (up to 13) or fatigue score (values 0–33) divided into four categories of spike IgG: <150 (n = 21), 150–4999 (n = 96), 5,000–20,000 (n = 103) and >20,000 (n = 92). 5k, 5,000; 20k, 20,000. g and h are violin plots of four categories of microneutralizing titers: <20 (neg n = 42), 20–79 (n = 107), 80–320 (n = 92) and >320 (n = 71). O2, supplemental oxygen.
Extended Data Fig. 1. Correlations between severity…
Extended Data Fig. 1. Correlations between severity of acute illness, antibody titres at 2 months and number of symptoms at 6 months follow-up.
Panel a is a scatter plot showing the correlation between severity of initial illness and the Spike IgG antibody titres (log 10) at 2 months follow-up. Panel b shows the correlation between Spike IgG antibody titres (log 10) at 2 months follow-up and the number of symptoms at 6 months follow-up, stratified by severity of initial illness, that is home-isolated versus hospitalised patients. A regression line calculated by linear model is shown in each graph with standard error represented by the shaded area.

References

    1. Gupta A, et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020;26:1017–1032. doi: 10.1038/s41591-020-0968-3.
    1. Meeting the challenge of long COVID. Nat. Med.26, 1803 (2020).
    1. Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
    1. Menni C, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat. Med. 2020;26:1037–1040. doi: 10.1038/s41591-020-0916-2.
    1. von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet. 2020;395:e109. doi: 10.1016/S0140-6736(20)31282-4.
    1. Venkatesan P. NICE guideline on long COVID. Lancet Respir. Med. 2021;9:129. doi: 10.1016/S2213-2600(21)00031-X.
    1. Lam MH, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch. Intern. Med. 2009;169:2142–2147. doi: 10.1001/archinternmed.2009.384.
    1. Kerr WR, Coghlan JD, Payne DJ, Robertson L. The laboratory diagnosis of chronic brucellosis. Lancet. 1966;2:1181–1183. doi: 10.1016/S0140-6736(66)90492-2.
    1. Ayres JG, Smith EG, Flint N. Protracted fatigue and debility after acute Q fever. Lancet. 1996;347:978–979. doi: 10.1016/S0140-6736(96)91470-1.
    1. Hanevik K, et al. Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study. Clin. Infect. Dis. 2014;59:1394–1400. doi: 10.1093/cid/ciu629.
    1. White PD, et al. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet. 2001;358:1946–1954. doi: 10.1016/S0140-6736(01)06961-6.
    1. Buchwald DS, Rea TD, Katon WJ, Russo JE, Ashley RL. Acute infectious mononucleosis: characteristics of patients who report failure to recover. Am. J. Med. 2000;109:531–537. doi: 10.1016/S0002-9343(00)00560-X.
    1. Seet RC, Quek AM, Lim EC. Post-infectious fatigue syndrome in dengue infection. J. Clin. Virol. 2007;38:1–6. doi: 10.1016/j.jcv.2006.10.011.
    1. Geense, W. W. et al. New physical, mental, and cognitive problems 1-year post-ICU: a prospective multicenter study. Am. J. Respir. Crit. Care Med.10.1164/rccm.202009-3381OC (2021).
    1. Kuwelker, K. et al. Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: a case-ascertained study. Lancet Reg. Health Eur.3, 100014 (2021).
    1. Robbiani DF, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437–442. doi: 10.1038/s41586-020-2456-9.
    1. Beigel JH, et al. Remdesivir for the treatment of Covid-19—final report. N. Engl. J. Med. 2020;383:1813–1826. doi: 10.1056/NEJMoa2007764.
    1. Chalder T, et al. Development of a fatigue scale. J. Psychosom. Res. 1993;37:147–153. doi: 10.1016/0022-3999(93)90081-P.
    1. Wessely S, Powell R. Fatigue syndromes: a comparison of chronic ‘postviral’ fatigue with neuromuscular and affective disorders. J. Neurol. Neurosurg. Psychiatry. 1989;52:940–948. doi: 10.1136/jnnp.52.8.940.
    1. Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–232. doi: 10.1016/S0140-6736(20)32656-8.
    1. Bellan M, et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw. Open. 2021;4:e2036142. doi: 10.1001/jamanetworkopen.2020.36142.
    1. Sykes DL, et al. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung. 2021;199:113–119. doi: 10.1007/s00408-021-00423-z.
    1. Venturelli S, et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. Epidemiol. Infect. 2021;149:e32. doi: 10.1017/S0950268821000145.
    1. Loge JH, Ekeberg O, Kaasa S. Fatigue in the general Norwegian population: normative data and associations. J. Psychosom. Res. 1998;45:53–65. doi: 10.1016/S0022-3999(97)00291-2.
    1. Fajnzylber J, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat. Commun. 2020;11:5493. doi: 10.1038/s41467-020-19057-5.
    1. Amanat F, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020;26:1033–1036. doi: 10.1038/s41591-020-0913-5.
    1. Trieu MC, et al. SARS-CoV-2-specific neutralizing antibody responses in Norwegian health care workers after the first wave of COVID-19 pandemic: a prospective cohort study. J. Infect. Dis. 2021;223:589–599. doi: 10.1093/infdis/jiaa737.

Source: PubMed

3
订阅